Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor

Journal Article · Tue Mar 15 04:00:00 EST 2005 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2004.12.020· OSTI ID:20696152

Bentzen, Lise ^[1]; Vestergaard-Poulsen, Peter ^[2]; Nielsen, Thomas ^[1]; Overgaard, Jens ^[1]; Bjornerud, Atle ^[3]; Briley-Saebo, Karen ^[4]; Horsman, Michael R ^[1]; Ostergaard, Leif ^[2]

---

1. Experimental Clinical Oncology, Arhus University Hospital, Arhus (Denmark)
2. Neuroradiology Research Unit, Arhus University Hospital, Arhus (Denmark)
3. Department of Radiology, Rikshospitalet, Oslo (Norway)
4. Amersham Health, Oslo (Norway)

Purpose: To examine the feasibility of using the MRI blood pool agent NC100150 for evaluation of tumor blood volume (TBV) estimates by both dynamic contrast-enhanced MRI (DCE-MRI) and susceptibility contrast MRI assays in an experimental tumor. Contrast agent clearance (K{sup trans}; depends on perfusion and permeability) from the DCE-MRI time curves was estimated, and changes in TBV and K{sup trans} were measured after administration of two drugs that reduce perfusion by different mechanisms. Methods and materials: The DCE-MRI experiments were simulated with expected physiologic values for the C3H mouse mammary carcinoma. The C3H tumor was examined by DCE-MRI and susceptibility contrast MRI with NC100150 (NC100150 Injection, Clariscan; Amersham Health, Oslo, Norway) after treatment with either hydralazine or combretastatin (Oxigene, Boston, MA). Results: Simulations showed that reliable estimates of changes in TBV and K{sup trans} could be performed with DCE-MRI. Hydralazine was shown to reduce TBV as measured by both assays and to reduce K{sup trans}. Dynamic contrast-enhanced MRI also suggested that TBV and K{sup trans} were reduced in combretastatin-treated tumors, and the TBV reduction was confirmed by susceptibility contrast MRI. Data suggested the drug to affect mainly the total TBV, whereas microvessels as such seemed less altered. Conclusion: The study supports the use of the combined DCE-MRI and susceptibility contrast MRI assay with a blood pool agent in characterizing tumors and their response to treatment.

• OSTI ID: 20696152
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 61; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BLOOD
CARCINOMAS
CLEARANCE
CONTRAST MEDIA
DRUGS
EVALUATION
MICE
NMR IMAGING
PERMEABILITY
PHOSPHATES